Journal article
Autoimmune diabetes from pembrolizumab: A case report and review of literature
World journal of clinical oncology, v 14(11), pp 535-543
24 Nov 2023
PMID: 38059185
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
BACKGROUNDImmunotherapy, specifically the use of checkpoint inhibitors such as pembrolizumab, has become an important tool in personalized cancer therapy. These inhibitors target proteins on T-cells that regulate the immune response against tumor cells. Pembrolizumab, which targets the programmed cell death 1 receptor on T-cells, has been approved for the treatment of metastatic melanoma and non-small cell lung cancer. However, it can also lead to immune-related side effects, including pneumonitis, colitis, thyroid abnormalities, and rare cases of type 1 diabetes.CASE SUMMARYThe case presented involves an adult patient in 30s with breast cancer who developed hyperglycemia after receiving pembrolizumab treatment. The patient was diagnosed with diabetic ketoacidosis and further investigations were performed to evaluate for new-onset type 1 diabetes. The patient had a history of hypothyroidism and a family history of breast cancer. Treatment for diabetic ketoacidosis was initiated, and the patient was discharged for close follow-up with an endocrinologist.CONCLUSIONThis literature review highlights the occurrence of diabetic ketoacidosis and new-onset type 1 diabetes in patients receiving pembrolizumab treatment for different types of cancer. Overall, the article emphasizes the therapeutic benefits of immunotherapy in cancer treatment, particularly pembrolizumab, while also highlighting the potential side effect of immune-related diabetes that can occur in a small percentage of patients. Here we present a case where pembrolizumab lead to development of diabetes after a few cycles highlighting one of the rare yet a serious toxicity of the drug.
Metrics
4 Record Views
Details
- Title
- Autoimmune diabetes from pembrolizumab: A case report and review of literature
- Creators
- Hardikkumar Bhanderi - Monmouth Medical CenterFarhan Khalid - Monmouth Medical CenterZubair Hassan Bodla - Florida CollegeTayyeb Muhammad - College Station Medical CenterDoantrang Du - Monmouth Medical CenterTrishala Meghal - Monmouth Medical Center
- Publication Details
- World journal of clinical oncology, v 14(11), pp 535-543
- Publisher
- Baishideng Publishing Group Inc
- Number of pages
- 9
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Pediatrics
- Web of Science ID
- WOS:001114412500005
- Other Identifier
- 991021930442004721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Web of Science research areas
- Oncology